Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18450%2F18%3A50014812" target="_blank" >RIV/62690094:18450/18:50014812 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00179906:_____/18:10382142
Výsledek na webu
<a href="http://dx.doi.org/10.2174/1567205015666180813150703" target="_blank" >http://dx.doi.org/10.2174/1567205015666180813150703</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/1567205015666180813150703" target="_blank" >10.2174/1567205015666180813150703</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Popis výsledku v původním jazyce
Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-beta (A beta) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Název v anglickém jazyce
Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Popis výsledku anglicky
Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-beta (A beta) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
10401 - Organic chemistry
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2018
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Current Alzheimer research
ISSN
1567-2050
e-ISSN
—
Svazek periodika
15
Číslo periodika v rámci svazku
12
Stát vydavatele periodika
AE - Spojené arabské emiráty
Počet stran výsledku
18
Strana od-do
1161-1178
Kód UT WoS článku
000448421000009
EID výsledku v databázi Scopus
2-s2.0-85054359977